Aeterna Zentaris Reports Third Quarter Financial and Operating Results

Go back to Aeterna Zentaris Reports Third Quarter Financial and Operating Results

UPDATE: Canaccord Genuity Upgrades AEterna Zentaris (AEZS) to Spec. Buy; Analyst Notes Removal of Dilution Overhang From Series B Warrants

November 9, 2015 6:42 AM EST

(Updated - November 9, 2015 10:49 AM EST)

Canaccord Genuity upgraded Æterna Zentaris (NASDAQ: AEZS) from Hold to Spec. Buy with a price target of $0.10. Analyst Neil Maruoka said the agreement to exercise the majority of the Series B warrants substantially removes the single largest overhang for the stock. He also thinks Zoptrex pivotal data before the end of 2016 will major catalyst for the stock.

Maruoka explained, "Since Æterna Zentaris last reporting date, its stock price has continued to decline, losing ~66% of its value at the most recent closing price of US$0.057. We... More

Aeterna Zentaris (AEZS) Misses Q3 EPS by 1c

November 5, 2015 5:00 PM EST

Aeterna Zentaris (NASDAQ: AEZS) reported Q3 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $0 versus the consensus estimate of $450 thousand.

For earnings history and earnings-related data on Aeterna Zentaris (AEZS) click here.

... More